Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways
Authors:
Top Cited Papers
- 5 December 2019
- journal article
- research article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 41 (5) , 670-677
Abstract
Renal fibrosis is considered as the pathway of almost all kinds of chronic kidney diseases (CKD) to the end stage of renal diseases (ESRD). Ganoderic acid (GA) is a group of lanostane triterpenes isolated from Ganoderma lucidum, which has shown a variety of pharmacological activities. In this study we investigated whether GA exerted antirenal fibrosis effect in a unilateral ureteral obstruction (UUO) mouse model. After UUO surgery, the mice were treated with GA (3.125, 12.5, and 50 mg· kg−1 ·d−1, ip) for 7 or 14 days. Then the mice were sacrificed for collecting blood and kidneys. We showed that GA treatment dose-dependently attenuated UUO-induced tubular injury and renal fibrosis; GA (50 mg· kg−1 ·d−1) significantly ameliorated renal disfunction during fibrosis progression. We further revealed that GA treatment inhibited the extracellular matrix (ECM) deposition in the kidney by suppressing the expression of fibronectin, mainly through hindering the over activation of TGF-β/Smad signaling. On the other hand, GA treatment significantly decreased the expression of mesenchymal cell markers alpha-smooth muscle actin (α-SMA) and vimentin, and upregulated E-cadherin expression in the kidney, suggesting the suppression of tubular epithelial-mesenchymal transition (EMT) partially via inhibiting both TGF-β/Smad and MAPK (ERK, JNK, p38) signaling pathways. The inhibitory effects of GA on TGF-β/Smad and MAPK signaling pathways were confirmed in TGF-β1-stimulated HK-2 cell model. GA-A, a GA monomer, was identified as a potent inhibitor on renal fibrosis in vitro. These data demonstrate that GA or GA-A might be developed as a potential therapeutic agent in the treatment of renal fibrosis.Keywords
This publication has 57 references indexed in Scilit:
- Renal interstitial fibrosisCurrent Opinion in Nephrology and Hypertension, 2012
- Prevalence of chronic kidney disease in China: a cross-sectional surveyThe Lancet, 2012
- Quality Difference Study of Six Varieties of Ganoderma lucidum with Different OriginsFrontiers in Pharmacology, 2012
- The Role of the p38 MAPK Signaling Pathway in High Glucose-Induced Epithelial-Mesenchymal Transition of Cultured Human Renal Tubular Epithelial CellsPLOS ONE, 2011
- Renal fibrosis: novel insights into mechanisms and therapeutic targetsNature Reviews Nephrology, 2010
- New Insights into Epithelial-Mesenchymal Transition in Kidney FibrosisJournal of the American Society of Nephrology, 2010
- Prevention of cisplatin induced nephrotoxicity by terpenes isolated from Ganoderma lucidum occurring in Southern Parts of IndiaExperimental and Toxicologic Pathology, 2009
- Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathyKidney International, 2009
- Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3β InactivationScience, 2008
- Activation of ERK in renal fibrosis after unilateral ureteral obstruction: Modulation by antioxidantsKidney International, 2005